Glucarpidase to combat toxic levels of methotrexate in patients

Therapeutics and Clinical Risk Management

Volumn 8, Issue , 2012, Pages 403-413

  Green, Jacalyn M ^a  

^a MIDWESTERN UNIVERSITY   (United States)

Author keywords

Antifolate; Carboxypeptidase G2; Chemotherapy; Glucarpidase; Methotrexate; References; Voraxaze

Indexed keywords

AMINO ACID; AMINOPTERIN; BACTERIAL ENZYME; CARBOXYPEPTIDASE G2; CREATININE; FOLIC ACID; FOLINIC ACID; GLUTAMIC ACID; METHOTREXATE; NITROGEN; UNCLASSIFIED DRUG; UREA; VORAXASE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALKALINIZATION; ALOPECIA; BONE MARROW SUPPRESSION; COMA; CRANIAL NERVE PARALYSIS; CREATININE BLOOD LEVEL; DEATH; DEMYELINATING DISEASE; DRUG EXCRETION; DRUG MEGADOSE; DRUG METABOLISM; DRUG STRUCTURE; ENZYME PURIFICATION; ERYTHEMA; FEVER; FLUSHING; FOOD AND DRUG ADMINISTRATION; HEADACHE; HUMAN; HYDRATION; HYPOTENSION; KIDNEY CLEARANCE; KIDNEY INJURY; LEUKEMIA; LIVER CIRRHOSIS; LIVER FIBROSIS; LYMPHOMA; MENINGISM; MUCOSA INFLAMMATION; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; PARALYSIS; PARESTHESIA; PHARMACOGENOMICS; PLEOCYTOSIS; PRURITUS; REVIEW; RHESUS MONKEY; SEIZURE; SIDE EFFECT; TISSUE INJURY; UNITED STATES; UREA NITROGEN BLOOD LEVEL; VOMITING;

EID: 84875359514     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: 10.2147/TCRM.S30135     Document Type: Review

References (77)

1. Hitchings GH, Burchall JJ. Inhibition of folate biosynthesis and function as a basis for chemotherapy. Adv Enzymol. 1965;27:417-468.
2. Carmel R. Folic acid. In: Shike M, Ross AC, editors. Modern Nutrition in Health and Disease. 10th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2006.
3. Bertino JR. Karnofsky memorial lecture. Ode to methotrexate. J Clin Oncol. 1993;11:5-14.
4. Heinle RW, Welch AD. Experiments with pteroylglutamic acid and pteroylglutamic acid deficiency in human leukemia. J Clin Invest. 1948;27:539.
5. Matherly LH, Hou Z, Deng Y. Human reduced folate carrier: translation of basic biology to cancer etiology and therapy. Cancer Metastasis Rev. 2007;26:111-128.
6. Chabner BA, Allegra CJ, Curt GA, et al. Polyglutamation of methotrexate. Is methotrexate a prodrug? J Clin Invest. 1985;76:907-912.
7. Rosenfelt F. Methotrexate and the need for continued research. Yale J Biol Med. 1975;48:97-103.
8. Skeel RT. Antineoplastic drugs and biologic response modifiers: classification, use, and toxicity of clinically useful agents. In: Skeel RT, editor. Handbook of Cancer Chemotherapy. 7th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2003.
9. Perry MC. The Chemotherapy Source Book. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2008.
10. Kemper AR, Van Mater HA, Coeytaux RR, Williams JW Jr, Sanders GD. Systematic review of disease-modifying antirheumatic drugs for juvenile idiopathic arthritis. BMC Pediatr. 2012;12:29.
11. Chabner BA, Allegra CJ. Antifolates. In: Chabner BA, Longo DL, editors. Cancer Chemotherapy and Biotherapy: Principles and Practice. 5th ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2010.
12. Treon SP, Chabner BA. Concepts in use of high-dose methotrexate therapy. Clin Chem. 1996;42:1322-1329.
13. Widemann BC, Adamson PC. Understanding and managing methotrexate nephrotoxicity. Oncologist. 2006;11:694-703.
14. Leveque D, Santucci R, Gourieux B, Herbrecht R. Pharmacokinetic drug-drug interactions with methotrexate in oncology. Expert Rev Clin Pharmacol. 2011;4:743-750.
15. Joerger M, Huitema AD, van den Bongard HJ, et al. Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients. Br J Clin Pharmacol. 2006;62:71-80.
16. Webb M. Inactivation of analogues of folic acid by certain non-exacting bacteria. Biochim Biophys Acta. 1955;17:212-225.
17. Levy CC, Goldman P. The enzymatic hydrolysis of methotrexate and folic acid. J Biol Chem. 1967;242:2933-2938.
18. Goldman P, Levy CC. Carboxypeptidase G: purification and properties. Proc Natl Acad Sci U S A. 1967;58:1299-1306.
19. Pratt AG, Crawford EJ, Friedkin M. The hydrolysis of mono-, di-, and triglutamate derivatives of folic acid with bacterial enzymes. J Biol Chem. 1968;243:6367-6372.
20. McCullough JL, Chabner BA, Bertino JR. Purification and properties of carboxypeptidase G1. J Biol Chem. 1971;246:7207-7213.
21. Albrecht AM, Boldizsar E, Hutchison DJ. Carboxypeptidase displaying differential velocity in hydrolysis of methotrexate, 5-methyltetrahydrofolic acid, and leucovorin. J Bacteriol. 1978;134:506-513.
22. Minton NP, Atkinson T, Sherwood RF. Molecular cloning of the Pseudomonas carboxypeptidase G2 gene and its expression in Escherichia coli and Pseudomonas putida. J Bacteriol. 1983;156: 1222-1227.
23. Minton NP, Atkinson T, Bruton CJ, Sherwood RF. The complete nucleotide sequence of the Pseudomonas gene coding for carboxypeptidase G2. Gene. 1984;31:31-38.
24. Sherwood RF, Melton RG, Alwan SM, Hughes P. Purification and properties of carboxypeptidase G2 from Pseudomonas sp. strain RS-16. Use of a novel triazine dye affinity method. Eur J Biochem. 1985;148:447-453.
25. Rowsell S, Pauptit RA, Tucker AD, Melton RG, Blow OM, Brick P. Crystal structure of carboxypeptidase G2, a bacterial enzyme with applications in cancer therapy. Structure. 1997;5:337-347.
26. Carter EL, Jager L, Gardner L, Hall CC, Willis S, Green JM. Escherichia coli abg genes enable uptake and cleavage of the folate catabolite p-aminobenzoyl-glutamate. J Bacteriol. 2007;189:3329-3334.
27. Green JM, Hollandsworth R, Pitstick L, Carter EL. Purification and characterization of the folate catabolic enzyme p-aminobenzoyl-glutamate hydrolase from Escherichia coli. J Bacteriol. 2010;192:2407-2413.
28. Hussein MJ, Green JM, Nichols BP. Characterization of mutations that allow p-aminobenzoyl-glutamate utilization by Escherichia coli. J Bacteriol. 1998;180:6260-6268.
29. Widemann BC, Sung E, Anderson L, et al. Pharmacokinetics and metabolism of the methotrexate metabolite 2, 4-diamino-N(10)-methylpteroic acid. J Pharmacol Exp Ther. 2000;294:894-901.
30. Monahan BP, Allegra CJ. Antifolates. In: Chabner BA, Longo DL, editors. Cancer Chemotherapy and Biotherapy: Principles and Practice. 4th ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2006.
31. Adamson PC, Balis FM, McCully CL, et al. Rescue of experimental intrathecal methotrexate overdose with carboxypeptidase-G2. J Clin Oncol. 1991;9:670-674.
32. Adamson PC, Balis FM, McCully CL, Godwin KS, Poplack DG. Methotrexate pharmacokinetics following administration of recombinant carboxypeptidase-G2 in rhesus monkeys. J Clin Oncol. 1992;10:1359-1364.
33. Chabner BA, Johns DG, Bertino JR. Enzymatic cleavage of methotrexate provides a method for prevention of drug toxicity. Nature. 1972;239:395-397.
34. Stoller RG, Hande KR, Jacobs SA, Rosenberg SA, Chabner BA. Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. N Engl J Med. 1977;297:630-634.
35. Hansen HH, Selawry OS, Holland JF, McCall CB. The variability of individual tolerance to methotrexate in cancer patients. Br J Cancer. 1971;25:298-305.
36. Zoubek A, Zaunschirm HA, Lion T, et al. Successful carboxypeptidase G(2) rescue in delayed methotrexate elimination due to renal failure. Pediatr Hematol Oncol. 1995;12:471-477.
37. Widemann BC, Balis FM, Murphy RF, et al. Carboxypeptidase-G2, thymidine, and leucovorin rescue in cancer patients with methotrexate-induced renal dysfunction. J Clin Oncol. 1997;15:2125-2134.
38. DeAngelis LM, Tong WP, Lin S, Fleisher M, Bertino JR. Carboxypeptidase G2 rescue after high-dose methotrexate. J Clin Oncol. 1996;14:2145-2149.
39. Krackhardt A, Schwartz S, Korfel A, Thiel E. Carboxypeptidase G2 rescue in a 79 year-old patient with cranial lymphoma after high-dose methotrexate induced acute renal failure. Leuk Lymphoma. 1999;35: 631-635.
40. Krause AS, Weihrauch MR, Bode U, et al. Carboxypeptidase-G2 rescue in cancer patients with delayed methotrexate elimination after high-dose methotrexate therapy. Leuk Lymphoma. 2002;43:2139-2143.
41. Widemann BC, Hetherington ML, Murphy RF, Balis FM, Adamson PC. Carboxypeptidase-G2 rescue in a patient with high dose methotrexate-induced nephrotoxicity. Cancer. 1995;76:521-526.
42. Park ES, Han KH, Choi HS, Shin HY, Ahn HS. Carboxypeptidase-G2 rescue in a patient with high dose methotrexate-induced nephrotoxicity. Cancer Res Treat. 2005;37:133-135.
43. Esteve MA, Devictor-Pierre B, Galy G, et al. Severe acute toxicity associated with high-dose methotrexate (MTX) therapy: use of therapeutic drug monitoring and test-dose to guide carboxypeptidase G2 rescue and MTX continuation. Eur J Clin Pharmacol. 2007;63:39-42.
44. Peyriere H, Cociglio M, Margueritte G, Vallat C, Blayac JP, Hillaire-Buys D. Optimal management of methotrexate intoxication in a child with osteosarcoma. Ann Pharmacother. 2004;38:422-427.
45. Qudsi R, Abdulhadi O, Sultan I. Low-dose carboxypeptidase-G2 for methotrexate toxicity in a child. Pediatr Blood Cancer. 2010;55: 1439-1440.
46. Vilay AM, Mueller BA, Haines H, Alten JA, Askenazi DJ. Treatment of methotrexate intoxication with various modalities of continuous extracorporeal therapy and glucarpidase. Pharmacotherapy. 2010;30:111.
47. Buchen S, Ngampolo D, Melton RG, et al. Carboxypeptidase G2 rescue in patients with methotrexate intoxication and renal failure. Br J Cancer. 2005;92:480-487.
48. Schwartz S, Borner K, Muller K, et al. Glucarpidase (carboxypeptidase g2) intervention in adult and elderly cancer patients with renal dysfunction and delayed methotrexate elimination after high-dose methotrexate therapy. Oncologist. 2007;12:1299-1308.
49. Widemann BC, Balis FM, Kim A, et al. Glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: clinical and pharmacologic factors affecting outcome. J Clin Oncol. 2010;28:3979-3986.
50. Christensen AM, Pauley JL, Molinelli AR, et al. Resumption of high-dose methotrexate after acute kidney injury and glucarpidase use in pediatric oncology patients. Cancer. 2012;118:4321-4380.
51. Widemann BC, Jayaprakash N, Howard SC, Daugherty C, Chauhan RK, Rush J. Clinical trial and compassionate use experience with glucarpidase for methotrexate toxicity. J Clin Oncol. 2012;Suppl 30: 6530.
52. Phillips M, Smith W, Balan G, Ward S. Pharmacokinetics of glucarpidase in subjects with normal and impaired renal function. J Clin Pharmacol. 2008;48:279-284.
53. Hempel G, Lingg R, Boos J. Interactions of carboxypeptidase G(2) with 6S-leucovorin and 6R-leucovorin in vitro: implications for the application in case of methotrexate intoxications. Cancer Chemother Pharmacol. 2005;55:347-353.
54. Levitt M, Mosher MB, DeConti RC, et al. Improved therapeutic index of methotrexate with "leucovorin rescue". Cancer Res. 1973;33: 1729-1734.
55. Bernard S, Etienne MC, Fischel JL, Formento P, Milano G. Critical factors for the reversal of methotrexate cytotoxicity by folinic acid. Br J Cancer. 1991;63:303-307.
56. Capizzi RL, DeConti RC, Marsh JC, Bertino JR. Methotrexate therapy of head and neck cancer: improvement in therapeutic index by the use of leucovorin "rescue". Cancer Res. 1970;30:1782-1788.
57. Goldin A, Mantel N, Greenhouse SW, Venditti JM, Humphreys SR. Effect of delayed administration of citrovorum factor on the antileukemic effectiveness of aminopterin in mice. Cancer Res. 1954;14: 43-48.
58. Bertino JR, Levitt M, McCullough JL, Chabner B. New approaches to chemotherapy with folate antagonists: use of leucovorin "rescue" and enzymic folate depletion. Ann N Y Acad Sci. 1971;186:486-495.
59. Binscheck T, Ambach L, Grobosch T, Schwartz S. Glucarpidase - a fast and efficient antidote in methotrexate poisoning. Clin Toxicol. 2010;48:299.
60. Voraxaze® (glucarpidase, full prescribing information). West Conshohocken, PA: BTG International Inc; 2012.
61. O'Marcaigh AS, Johnson CM, Smithson WA, et al. Successful treatment of intrathecal methotrexate overdose by using ventriculolumbar perfusion and intrathecal instillation of carboxypeptidase G2. Mayo Clin Proc. 1996;71:161-165.
62. Widemann BC, Balis FM, Shalabi A, et al. Treatment of accidental intrathecal methotrexate overdose with intrathecal carboxypeptidase G2. J Natl Cancer Inst. 2004;96:1557-1559.
63. Gervasini G. Polymorphisms in methotrexate pathways: what is clinically relevant, what is not, and what is promising. Curr Drug Metab. 2009;10:547-566.
64. Castaldo P, Magi S, Nasti AA, et al. Clinical pharmacogenetics of methotrexate. Curr Drug Metab. 2011;12:278-286.
65. Chabner BA, Chello PL, Bertino JR. Antitumor activity of a folate-cleaving enzyme, carboxypeptidase G1. Cancer Res. 1972;32: 2114-2119.
66. Kalghatgi KK, Moroson BA, Horvath C, Bertino JR. Enhancement of antitumor activity of 2,4-diamino-5-(3′,4′-dichlorophenyl)-6-methylpyrimidine and Baker's antifol (triazinate) with carboxypeptidase G1. Cancer Res. 1979;39:3441-3445.
67. Romanini A, Sobrero AF, Chou TC, Sherwood RF, Bertino JR. Enhancement of trimetrexate cytotoxicity in vitro and in vivo by carboxypeptidase G2. Cancer Res. 1989;49:6019-6023.
68. Melton RG, Wiblin CN, Baskerville A, Foster RL, Sherwood RF. Covalent linkage of carboxypeptidase G2 to soluble dextrans-II. In vivo distribution and fate of conjugates. Biochem Pharmacol. 1987;36: 113-121.
69. Bagshawe KD, Springer CJ, Searle F, et al. A cytotoxic agent can be generated selectively at cancer sites. Br J Cancer. 1988;58:700-703.
70. Searle F, Bier C, Buckley RG, et al. The potential of carboxypeptidase G2-antibody conjugates as anti-tumour agents. I. Preparation of antihuman chorionic gonadotrophin-carboxypeptidase G2 and cytotoxicity of the conjugate against JAR choriocarcinoma cells in vitro. Br J Cancer. 1986;53:377-384.
71. Melton RG, Searle F, Sherwood RF, Bagshawe KD, Boden JA. The potential of carboxypeptidase G2: antibody conjugates as anti-tumour agents. II. In vivo localising and clearance properties in a choriocarcinoma model. Br J Cancer. 1990;61:420-424.
72. Senter PD. Activation of prodrugs by antibody-enzyme conjugates: a new approach to cancer therapy. FASEB J. 1990;4:188-193.
73. Blakey DC, Davies DH, Dowell RI, et al. Anti-tumour effects of an antibody-carboxypeptidase G2 conjugate in combination with phenol mustard prodrugs. Br J Cancer. 1995;72:1083-1088.
74. Pedley RB, Sharma SK, Hawkins RE, Chester KA. Antibody-directed enzyme-prodrug therapy. Methods Mol Med. 2004;90:491-514.
75. Davies LC, Friedlos F, Hedley D, et al. Novel fluorinated prodrugs for activation by carboxypeptidase G2 showing good in vivo antitumor activity in gene-directed enzyme prodrug therapy. J Med Chem. 2005;48:5321-5388.
76. Hedley D, Ogilvie L, Springer C. Carboxypeptidase-G2-based gene-directed enzyme-prodrug therapy: a new weapon in the GDEPT armoury. Nat Rev Cancer. 2007;7:870-879.
77. Hunter P. The fourth front against cancer. The first clinical trials to test engineered viruses that attack tumour cells have yielded promising results for future cancer therapies. EMBO Rep. 2011;12:769-771.